Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gastric Cancer
  Free Subscription

Articles published in
Br J Cancer
    August 2025
  1. LI L, Yin J, Zhang L, Liu W, et al
    Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor.
    Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03145.
    >> Share

  2. SHI D, Liu W, Sun L, Zhao X, et al
    LMP2A regulates S901 phosphorylation of EphA2 to maintain EBV latent infection in gastric cancer.
    Br J Cancer. 2025 Aug 9. doi: 10.1038/s41416-025-03131.
    >> Share

  3. WANG B, Wang Y, Zhu Y, Guo L, et al
    Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.
    Br J Cancer. 2025;133:255-269.
    >> Share

    July 2025
  4. ZHOU J
    Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03100.
    >> Share

  5. YANG C, Gao Z, Tang R, Zhou L, et al
    POU6F2 promotes liver metastasis of gastric adenocarcinoma by dual mechanism of transcriptional upregulation of SNAI1 and IGF2/PI3K/AKT signaling-induced conversion of hepatic stellate cells into cancer-associated fibroblasts.
    Br J Cancer. 2025;133:14-26.
    >> Share

    June 2025
  6. ZHAO R, Xie J, Chen H, Gong X, et al
    VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.
    Br J Cancer. 2025 Jun 23. doi: 10.1038/s41416-025-03081.
    >> Share

  7. LEE KW, Zang DY, Kim HD, Kim JW, et al
    Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Br J Cancer. 2025 Jun 20. doi: 10.1038/s41416-025-03092.
    >> Share

    May 2025
  8. LEE KW, Zang DY, Kim HD, Kim JW, et al
    Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Br J Cancer. 2025 May 21. doi: 10.1038/s41416-025-03052.
    >> Share

  9. GROEN-VAN SCHOOTEN TS, Cabeza-Segura M, Ferreira RM, Martinez-Ciarpaglini C, et al
    Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.
    Br J Cancer. 2025;132:783-792.
    >> Share

    April 2025
  10. SUN M, Gu Y, Wang J, Zhang Z, et al
    Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer.
    Br J Cancer. 2025 Apr 25. doi: 10.1038/s41416-025-03002.
    >> Share

  11. LI J, Tao M, Liu L, Liu C, et al
    Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.
    Br J Cancer. 2025 Apr 17. doi: 10.1038/s41416-025-03015.
    >> Share

  12. LU J, Chen Y, Liu X, Wang J, et al
    Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.
    Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-02984.
    >> Share

    March 2025
  13. TSUTSUMI C, Ohuchida K, Yamada Y, Shimada Y, et al
    Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.
    Br J Cancer. 2025 Mar 24. doi: 10.1038/s41416-025-02981.
    >> Share

    September 2024
  14. CHEN C, Han J, He Q, Yao Q, et al
    Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.
    Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02835.
    >> Share

  15. KANDA M, Kasahara Y, Shimizu D, Shinozuka T, et al
    Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer.
    Br J Cancer. 2024 Sep 20. doi: 10.1038/s41416-024-02859.
    >> Share

    August 2024
  16. GU Y, Sun M, Fang H, Shao F, et al
    Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02825.
    >> Share

    July 2024
  17. FANG M, Lin Y, Xue C, Sheng K, et al
    The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
    Br J Cancer. 2024 Jul 13. doi: 10.1038/s41416-024-02778.
    >> Share

  18. HARA Y, Baba Y, Oda E, Harada K, et al
    Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02753.
    >> Share

  19. ANGERILLI V, Sabella G, Simbolo M, Lagano V, et al
    Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Br J Cancer. 2024;131:159-170.
    >> Share

    June 2024
  20. LI X, Xie G, Chen J, Wang Y, et al
    Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.
    Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02735.
    >> Share

    May 2024
  21. MURPHY JD, Gadalla SM, Anderson LA, Rabkin CS, et al
    Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom.
    Br J Cancer. 2024 May 22. doi: 10.1038/s41416-024-02714.
    >> Share

    March 2024
  22. SUH YS, Lee J, George J, Seol D, et al
    RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02642.
    >> Share

    February 2024
  23. SAITO T, Kurokawa Y, Fujitani K, Kawabata R, et al
    Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
    Br J Cancer. 2024 Feb 7. doi: 10.1038/s41416-023-02540.
    >> Share

  24. CECCHINI M, Cleary JM, Shyr Y, Chao J, et al
    NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
    Br J Cancer. 2024;130:476-482.
    >> Share

  25. GROSSER B, Emmerson J, Reitsam NG, Cunningham D, et al
    Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Br J Cancer. 2024;130:457-466.
    >> Share

    January 2024
  26. WANG J, Sun N, Kunzke T, Shen J, et al
    Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.
    Br J Cancer. 2024 Jan 24. doi: 10.1038/s41416-023-02559.
    >> Share

  27. CAI F, Yang X, Ma G, Wang P, et al
    EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-kappaB signalling activation independent of hydroxylase activity.
    Br J Cancer. 2024 Jan 6. doi: 10.1038/s41416-023-02546.
    >> Share

    December 2023
  28. KAMIYA H, Komatsu S, Takashima Y, Ishida R, et al
    Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02532.
    >> Share

    November 2023
  29. ALLAN Z, Witts S, Tie J, Tebbutt N, et al
    The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.
    Br J Cancer. 2023;129:1717-1726.
    >> Share

    August 2023
  30. CHEN T, Li D, Wang Y, Shen X, et al
    Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1alpha-FBLN5 signaling pathway.
    Br J Cancer. 2023 Aug 29. doi: 10.1038/s41416-023-02409.
    >> Share

  31. ANDO K, Nakamura Y, Kitao H, Shimokawa M, et al
    Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
    Br J Cancer. 2023 Aug 2. doi: 10.1038/s41416-023-02378.
    >> Share

    July 2023
  32. LIU X, Lv K, Wang J, Lin C, et al
    C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02336.
    >> Share

  33. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    >> Share

    June 2023
  34. DONG X, Fan J, Xie W, Wu X, et al
    Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02319.
    >> Share

    April 2023
  35. LIU DHW, Kim YW, Sefcovicova N, Laye JP, et al
    Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.
    Br J Cancer. 2023 Apr 7. doi: 10.1038/s41416-023-02257.
    >> Share

  36. LAAKSONEN MA, Li S, Canfell K, MacInnis RJ, et al
    The future burden of oesophageal and stomach cancers attributable to modifiable behaviours in Australia: a pooled cohort study.
    Br J Cancer. 2023;128:1052-1069.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016